En la Selección de artículos colaboró el Dr. Joao Baptista de Palma

           AMERICAN JOURNAL OF CLINICAL ONCOLOGY 2020 43 (2)

1. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Recurrence. Pág. 73-81.

2.   A Limited-Versus-Extensive Staging Strategy for Small Cell Prostate Cancer. Pág. 87-93.

3. Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma. Pág. 115-121.

4. Expanding the Spectrum of Radiation Necrosis After Stereotactic Radiosurgery (SRS) for Intracranial Metastases From Lung Cancer. Pág. 128-132.

5. Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma. Pág. 139-145.

            ANNALS OF SURGICAL ONCOLOGY 2020 27 (3)

6. Clinicopathologic Characteristics of Oligometastases from Esophageal Cancer and Long-Term Outcomes of Resection.Pág. 651-659.

7. Utility of Radiation After Neoadjuvant Chemotherapy for Surgically Resectable Esophageal Cancer. Pág. 662-670.

8. Impact of Lymphadenectomy on Survival After Unimodality Transthoracic Esophagectomy for Adenocarcinoma of Esophagus. Pág. 692-700.

9. Surgical and Surgeon-Related Factors Related to Long-Term Survival in Esophageal Cancer: A Review. Pág. 718-723.

10. The Landmark Series: Axillary Management in Breast Cancer. Pág. 724-729.

11. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Pág. 765-771.

12. Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?. Pág. 783-792.

13. The Suggestion of Revised Criteria for Endoscopic Resection of Differentiated-Type Submucosal Gastric Cancer. Pág. 795-801.

14. Long-Term Survival after Minimally Invasive Versus Open Gastrectomy for Gastric Adenocarcinoma: A Propensity ScoreMatched Analysis of Patients in the United States and China. Pág. 802-811.

15. Perioperative Blood Transfusion is Associated with Postoperative Systemic Inflammatory Response and Poorer Outcomes Following Surgery for Colorectal Cancer. Pág. 833-843.

16. Fong’s Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial. Pág. 877-885.

17. Conservative Re-excision is a Safe and Simple Alternative to Radical Resection in Revision Surgery for Dermatofibrosarcoma Protuberans. Pág. 919-923.

18. Neurologic Complications of Melanoma. Pág. 477-486.

19. Fertility Preservation Before Breast Cancer Treatment Appears Unlikely to Affect Disease-Free Survival at a Median Follow-Up of 43 Months After Fertility-Preservation Consultation. Pág. 487-495.

20. Intracranial Antitumor Activity With Encorafenib Plus Binimetinib in Patients With Melanoma Brain Metastases: A Case Series. Pág. 523-530.

21. Clinical Utility of Hereditary Cancer Panel Testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D Results on Patient Management and Adherence to Provider Recommendations. Pág. 549-558.

22. Impact of Multimorbidity Subgroups on the Health Care Use of Early Pediatric Cancer Survivors. Pág. 649-658.

23. Risk Factors for Cardiovascular Disease in 5-Year Survivors of Adolescent and Young Adult Cancer: A Danish Population-Based Cohort Study. Pág. 659-669.

24. Magnitude of Reduction in Risk of Second Contralateral Breast Cancer With Bilateral Mastectomy in Patients With Breast Cancer: Data From California, 1998 Through 2015. Pág. 959-970.

25. Nab-Paclitaxel in Older Patients With Non–Small Cell Lung Cancer Who Have Developed Disease Progression After Platinum-Based Doublet Chemotherapy. Pág. 1060-1067.

JOURNAL OF CLINICAL ONCOLOGY 2020 38 (3)

26. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Pág. 193-202.

27. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). Pág. 203-213.

28. Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study. Pág. 214-222.

29. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. Pág. 248-256.

30. Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 3 2, Phase II Trial. Pág. 257-270.

JOURNAL OF CLINICAL ONCOLOGY 2020 38 (4)

31. Impact of Cancer on Employment. Pág. 302-309.

32. Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs. Pág. 351-358.

33. Charting the Course: Use of Clinical Pathways to Improve Value in Cancer Care. Pág. 367-371.

34. Review of Current Policy Strategies to Reduce US Cancer Drug Costs. Pág. 372-379.

35. Understanding Financial Hardship Among Cancer Survivors in the United States: Strategies for Prevention and Mitigation. Pág. 292-301.

JOURNAL OF CLINICAL ONCOLOGY 2020 38 (5)

36. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. Pág. 388-394.

37. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. Pág. 395-405.

38. Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. Pág. 406-414.

39. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Pág. 423-433.